Tislelizumab plus chemotherapy and radiotherapy yields 89.1% 3-year disease-free survival in pMMR/MSS locally advanced rectal cancer
Early trial shows high survival rates for rectal cancer patients treated with tislelizumab
This Phase 2 clinical trial evaluated neoadjuvant tislelizumab, chemotherapy, and long-course radiotherapy in 50 patients with pMMR/MSS loca…
A Phase 2 trial found that adding tislelizumab to standard care helped 89% of patients stay free of cancer for three years. This approach wo…
Deep hyperthermia with tislelizumab and chemotherapy in advanced squamous NSCLC
Deep Heat Plus Drug Boosts Lung Cancer Response Rates
This retrospective cohort study of 100 patients with advanced squamous NSCLC evaluated deep hyperthermia combined with tislelizumab and chem…
Adding deep heat to standard lung cancer treatment improved response rates significantly while keeping safety levels the same as standard ch…
Randomized Phase II Trial Evaluates Ociperlimab Plus Tislelizumab and BAT1706 in Advanced Hepatocellular Carcinoma
Adding a new drug did not help liver cancer patients survive longer
This randomized phase II trial enrolled 94 patients with advanced hepatocellular carcinoma. The objective response rate was 37.1% for ociper…
A new drug combination showed promise for advanced liver cancer, but adding a third drug did not improve results.
Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort
Sintilimab May Be Safer Lung Cancer Treatment
This retrospective cohort study evaluated 409 patients with stage IIIB-IV non-small cell lung cancer receiving PD-1 inhibitors. In nonsquamo…
One lung cancer drug may cause fewer serious side effects than others while working just as well, a real-world study suggests.
Case report suggests grade 3 ICI-induced inflammatory arthritis may correlate with sustained response to tislelizumab in advanced head and neck carcinoma.
Could a painful joint flare actually signal that cancer treatment is working long-term?
This case report and literature review describes a single patient with advanced unknown primary carcinoma of the head and neck receiving mai…
A patient with advanced head and neck cancer stayed in complete remission for over a year after joint pain from treatment forced doctors to …
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors
Rare cervical melanoma cases show mixed results with immunotherapy and surgery
A case report of two patients with primary malignant melanoma of the cervix and a review of nine reported cases treated with PD-1/PD-L1 inhi…
Surgery alone fails for rare cervical melanoma, as 80% of patients progress on immunotherapy without chemotherapy or radiation.
BACE plus tislelizumab shows activity in advanced NSCLC patients ineligible for standard care
Combination treatment shows promise for advanced lung cancer patients ineligible for standard care
A Phase II, single-arm trial in 30 patients with Stage IIIA-IIIC NSCLC who refused or were ineligible for standard treatment evaluated bronc…
A new combo treatment for advanced lung cancer patients ineligible for standard care helped 60% shrink tumors and extended survival to 15 mo…
Phase II studies evaluate tislelizumab plus sitravatinib or anlotinib maintenance in extensive-stage small-cell lung cancer.
Can adding two drugs after chemo help some lung cancer patients survive longer?
These prospective phase II single-arm studies assessed tislelizumab combined with sitravatinib or anlotinib as maintenance therapy in previo…
Adding tislelizumab plus sitravatinib or anlotinib after chemo kept some small-cell lung cancer patients cancer-free for 6.4 to 7.8 months.
Perioperative tislelizumab plus chemotherapy improves survival in Chinese patients with resectable NSCLC
Tislelizumab with chemotherapy before surgery improves survival in Chinese lung cancer patients
In a phase III RCT of 453 Chinese adults with resectable stage II-IIIA NSCLC, perioperative tislelizumab plus neoadjuvant chemotherapy signi…
Adding tislelizumab to chemotherapy before surgery helped Chinese lung cancer patients live longer, with a 79.3% three-year survival rate ve…